China's CanSino defends coronavirus vaccine candidate after experts cast doubt - (Yahoo!News via NewsPoints Desk)

  • CanSino Biologics said on Wednesday that expert opinion on its COVID-19 vaccine candidate should not be followed "blindly" without sufficient clinical trial data, as reported Yahoo!News.

  • Scientists have expressed concern that the effectiveness of CanSino's candidate Ad5-nCoV could be limited, as existing antibodies against the common cold virus might undermine Ad5-nCoV.

  • "Vaccine development is a practice-based science, and we should not blindly follow experts," chief scientific officer Zhu Tao said.

  • No evidence has shown that existing antibodies against the common cold could have a major adverse impact on the vaccine candidate's ability to trigger antibodies against the novel coronavirus, Zhu added.

To read more NewsPoints articles, click here.